Competing interests
DISEASE, ABUSE
JSH has received grant funding from the Centers for Disease Control and Prevention (CDC) (R01CE003006). SER and KFK have received grant funding from Gilead Sciences, Inc. JRM has received grant funding from the National Institute on Drug Abuse (NIDA) (P30DA040500). EMG serves as site principal investigator for clinical trials sponsored by Cepheid, Gilead Science, and Viiv Healthcare. MSL and DAEW receive investigator-initiated grant support paid to the institution from Gilead Sciences. All other authors report no conflicts of interest.